MedTrace Logo

Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria

NCT02411994 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2017-11-27

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children.

Conditions

Interventions

DRUG

Pyronaridine-artesunate

DRUG

Artemether-lumefantrine combination

Sponsors & Collaborators

  • Royal Tropical Institute

    lead OTHER

Principal Investigators

  • Patrick Sawa, MD, PhD · International Centre of Insect Physiology and Ecology (ICIPE)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02411994 on ClinicalTrials.gov